Demet Cekdemir; Serkan Guvenc; Fusun Ozdemirkiran; Ali Eser; Tayfur Topts; Vildan Ozkocaman; Handan Haydaroglu Sahin; Esra Ermis Turak; Ramazan Esen; Melda Comert; Sevil Sadrilo; Muzeyyen Aslaner; Bahar Uncu Ulu; Abdullah Karakus; Derya Selim Bapur; Inci Alacacioglu; Demet Aydin; Atakan Tekinalp; Sinem Namdaroglu; Funda Ceran; Pinar Tarkun; Demet Kiper; Mustafa Cetiner; Mustafa Yenerel; Ahmet Muzaffer Demir; Guven Yilmaz; Hatice Terzi; Erden Atilla; Umit Yavuz Malkan; Kadir Acar; Erman Ozturk; Anil Tombak; Cenk Sunu; Ozan Salim; Nevin Alayvaz; Ozkan Sayan; Ulku Ozan; Mesut Ayer; Zafer Gokgoz; Neslihan Andic; Ebru Kizilkilic; Figen Noyan; Özen, Mehmet; Funda Pepedil Tanrikulu; Guchan Alanoglu; Hasan Atilla Ozkan; Vahap Aslan; Guven Cetin; Alev Akyol Erikci; Burak Deveci; Fadime Ersoy Dursun; Hasan Dermenci; Pelin Aytan; Gündüz, Mehmet; Volkan Karakus; Can Ozlu; Sinan Demircioglu; Olga Meltem Akay Yanar; Duzgun Ozatli; Levent Undar; Eyup Naci Tiftik; Eayhan Gulsan Turkoz Sucak; Ibrahim Haznedaroglu; Muhit Ozcan; Mehmet Sencan; Murat Tombuloglu; Gulsum Ozet; Oktay Bilgir; Burhan Turgut; Mehmet Ali Ozcan; Kadriye Bahriye Payzin; Mehmet Sonmez; Eorhan Ayyildiz; Mehmet Sinan Dal; Sehmus Ertop; Mehmet Turgut; Teoman Soysal; Emin Kaya; Ali Unal; Mustafa Pehlivan; Isik Atagunduz; Tulin Tuglular Firatli; Guray Saydam; Reyhan Diz Kucukkaya
(GALENOS YAYINCILIK, 2019)
Conclusion: Results of the current study imply that eltrombopag is an effective therapeutic option even in elderly patients with chronic ITP. However, patients must be closely monitored for response and side effects during ...